These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 31319988)

  • 1. First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light.
    Ackermann CJ; Reck M; Paz-Ares L; Barlesi F; Califano R
    Lung Cancer; 2019 Aug; 134():245-253. PubMed ID: 31319988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
    Dafni U; Tsourti Z; Vervita K; Peters S
    Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer.
    Puri S; Shafique M; Gray JE
    Curr Treat Options Oncol; 2018 Jun; 19(8):39. PubMed ID: 29931587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer.
    Saxena P; Singh PK; Malik PS; Singh N
    Curr Treat Options Oncol; 2020 Jul; 21(8):69. PubMed ID: 32720019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rational application of the first-line chemotherapy and immune checkpoint inhibitors in advanced nonsmall cell lung cancer: A meta-analysis.
    Cao R; Ma JT; Zhang SL; Sun L; Liu Y; Zhang XY; Jing W; Huang LT; Han CB
    Cancer Med; 2019 Sep; 8(11):5033-5046. PubMed ID: 31297962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer.
    Kuo CS; Wang CC; Huang YC; Pavlidis S; Liu CY; Ko HW; Chung FT; Lin TY; Wang CL; Guo YK; Yang CT
    Thorac Cancer; 2019 May; 10(5):1158-1166. PubMed ID: 30950239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer.
    Santana-Davila R; Chow LQ
    Future Oncol; 2018 Feb; 14(3):191-194. PubMed ID: 29334785
    [No Abstract]   [Full Text] [Related]  

  • 8. Impact of the microbiome on checkpoint inhibitor treatment in patients with non-small cell lung cancer and melanoma.
    Shaikh FY; Gills JJ; Sears CL
    EBioMedicine; 2019 Oct; 48():642-647. PubMed ID: 31597596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Schvartsman G; Peng SA; Bis G; Lee JJ; Benveniste MFK; Zhang J; Roarty EB; Lacerda L; Swisher S; Heymach JV; Fossella FV; William WN
    Lung Cancer; 2017 Oct; 112():90-95. PubMed ID: 29191606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current strategies incorporating immune checkpoint inhibitors for the treatment of advanced or metastatic non-small-cell lung cancers.
    Motta G; Vigneri P
    Future Oncol; 2019 Sep; 15(27):3097-3101. PubMed ID: 31573839
    [No Abstract]   [Full Text] [Related]  

  • 11. The efficacy and safety of anti-PD-1/PD-L1 antibodies combined with chemotherapy or CTLA4 antibody as a first-line treatment for advanced lung cancer.
    Xu X; Huang Z; Zheng L; Fan Y
    Int J Cancer; 2018 Jun; 142(11):2344-2354. PubMed ID: 29318609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-Line Immune Checkpoint Inhibition for Advanced Non-Small-Cell Lung Cancer: State of the Art and Future Directions.
    Ackermann CJ; Adderley H; Ortega-Franco A; Khan A; Reck M; Califano R
    Drugs; 2020 Nov; 80(17):1783-1797. PubMed ID: 32986224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durvalumab in non-small-cell lung cancer patients: current developments.
    Mezquita L; Planchard D
    Future Oncol; 2018 Feb; 14(3):205-222. PubMed ID: 29140105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Checkpoint Inhibitor Therapy: What Line of Therapy and How to Choose?
    Ramamurthy C; Godwin JL; Borghaei H
    Curr Treat Options Oncol; 2017 Jun; 18(6):33. PubMed ID: 28534248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy.
    Zhou Y; Lin Z; Zhang X; Chen C; Zhao H; Hong S; Zhang L
    J Immunother Cancer; 2019 May; 7(1):120. PubMed ID: 31053172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint inhibitors: For how long do we need to release the brakes to achieve the optimum acceleration of immune-mediated anti-tumor response?
    Sukari A; Nagasaka M
    Oral Oncol; 2020 Feb; 101():104435. PubMed ID: 31635973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of Immunotherapy.
    Ragavan M; Das M
    Curr Treat Options Oncol; 2020 Jun; 21(8):64. PubMed ID: 32601742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer.
    Shien K; Papadimitrakopoulou VA; Wistuba II
    Lung Cancer; 2016 Sep; 99():79-87. PubMed ID: 27565919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.
    Hoffner B; Leighl NB; Davies M
    Cancer Treat Rev; 2020 Apr; 85():101979. PubMed ID: 32078962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.